Normally, the SOD1 protein provides protective benefits to the brain but, in Parkinson’s patients, it becomes faulty, causing the protein to clump and damage brain cells.

Normally, the SOD1 protein provides protective benefits to the brain but, in Parkinson's patients, it becomes faulty, causing the protein to clump and damage brain cells.

A new drug originally developed to treat a different brain disease is now showing signs that it could help people with ...

As reported in 1994, the original SOD1-G93A strain, designated G1, expressed approximately 18 copies of human SOD1, randomly inserted into the genome (Gurney et al., 1994). An unequal crossover event ...

A total of 87 subjects (45 men and 42 women) with an age range from 16–73 years of age were studied. RESULTS There was no detectable difference in the number of motor units in SOD1 mutation carriers ...

Ionis has been at the forefront of discovering and developing leading neurological disease medicines, including SPINRAZA ® (nusinersen), the first approved treatment for spinal muscular atrophy, ...

SOD1-ALS disease progression may slow with RAG-17: Final trial data An experimental candidate by Ractigen Therapeutics to treat amyotrophic lateral sclerosis (ALS) linked to mutations in the SOD1 gene ...

The correlation between miR-214 and inflammatory markers, including NfL, underscores its role in neuroinflammation. miR-214 is elevated in microglia from SOD1-G93A mice, 15 patient with ALS muscles 16 ...

Dr Jonathan Berg Dr Siobhan Kerr Benatar M, Wuu J, Andersen P, Bucelli R, Andrews J, Otto M et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically ...